Novartis AG Eyes Israeli Companies
Novartis AG (NYSE: NVS), the world's biggest pharmaceutical company, recently increased its interest in Israel. For a long time, the company was active in marketing and clinical trials in Israel, and now it is involved in investment as well.
Over the past year, Novartis has invested $35 million in Israel’s Gamida Cell, with an option to acquire it in the future for $165 million, plus royalties, by mid-2016. Novartis also signed a deal with BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX), under which BioLineRx will seek and develop Israeli technologies for Novartis.
Help employers find you! Check out all the jobs and post your resume.
Over the past year, Novartis has invested $35 million in Israel’s Gamida Cell, with an option to acquire it in the future for $165 million, plus royalties, by mid-2016. Novartis also signed a deal with BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX), under which BioLineRx will seek and develop Israeli technologies for Novartis.
Help employers find you! Check out all the jobs and post your resume.